Novo Nordisk A/S – Page 3

How Much Do Ozempic and Wegovy Cost? Not What You Think.

Drug companies are making billions from a new class of in-demand weight-loss treatments. But the prices are not what they seem.

By Gina Kolata

Health Insurance and Managed Care Medicare Novo Nordisk A/S Obesity Semaglutide (Drug) Suits and Litigation (Civil)

Lawsuit Challenges Insurance Restrictions on Weight Loss Drugs Like Wegovy

Many employers and government programs won’t cover costly obesity medications. A lawsuit is challenging one such policy.

By Rebecca Robbins

Denmark Diabetes Drugs (Pharmaceuticals) Economic Conditions and Trends Gross Domestic Product Novo Nordisk A/S Ozempic (Drug) Semaglutide (Drug) Wegovy

Novo Nordisk’s Ozempic and Wegovy Reshape Denmark’s Economy

Novo Nordisk, the Danish company behind two popular obesity medications, is reaping huge profits and is now responsible for most of the country’s economic growth.

By Eshe Nelson

Diabetes Drugs (Pharmaceuticals) Heart Mikhail Kosiborod New England Journal of Medicine Novo Nordisk A/S Obesity Placebos Research Semaglutide (Drug) Weight

Wegovy, the Weight Loss Drug, Relieves Heart Failure Symptoms: Drugmaker’s Study

The drug Wegovy eased issues for people with a type of heart problem, adding to the treatment’s benefits beyond weight loss.

By Benjamin Mueller

mosaec